Jubilant Ingrevia Limited has informed the Exchange about General Updates
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Smallcap 250 and 0.9 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Ingrevia has completed the acquisition of 100% equity stake in Remidex Pharma Private Limited, pursuant to the Share Purchase Agreement signed on March 13, 2026. The company states that all required details under SEBI Listing Regulations were already disclosed in its earlier intimation dated March 13, 2026. No new financial terms or conditions were provided in this update, as it serves as a confirmation of deal completion. The event occurred on March 30, 2026, and the filing has been made under Regulation 30 of the SEBI LODR.
Shareholders should view this as a confirmed bolt-on acquisition that strengthens Jubilant Ingrevia's pharmaceutical/API business. Since Remidex is a private unlisted company, no open offer obligation is triggered for public shareholders.